Amgen Inc And UCB SA announces Romosozumab phase 2 data published in New England Journal Of Medicine Show significant increases in bone mineral density at both spine and hip

Wednesday, 1 Jan 2014 05:00pm EST 

Amgen Inc and UCB SA:Says results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).Says published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck.Says significant increases were also observed in the first BMD assessment at three months.Says moreover, in exploratory analyses, increases observed at the lumbar spine and hip were significantly greater than those observed with current treatments FOSAMAX (alendronate sodium) and FORTEO/FORSTEO (teriparatide).Says in this phase 2 trial, each of the five romosozumab dose regimens significantly increased BMD compared with pooled placebo groups at the lumbar spine, total hip and femoral neck regions (all p <0.001). 

Company Quote

-4.11 -2.63%
30 Jan 2015